LENALIDOMIDA (Revlimid): riesgo de nuevos tipos de neoplasias .

7 de mayo de 2012
FDA Drug Safety Communication: Safety review update of cancer drug Revlimid (lenalidomide) and risk of developing new types of malignancies.